Experiences with
Trametinib29 public posts
Your experiences of trametinib needed (online survey)
If you have been diagnosed with low grade serous ovarian cancer and you have been prescribed trametinib as part of your treatment, it would be great to hear from you. We would also love to hear experiences from friends, family members and carers.
Want to take advantage of all our features? Just log in!
or
Update on trametinib (Mekinist) for low grade serous ovarian cancer
Trametinib is a targeted therapy which blocks a protein that helps cancer cells grow.
Off-label drugs are prescribed by doctors in a different way than the conditions in its licence.
BRA/ Mek Treatment holiday flops in late stage melanoma trial
In the phase II study of over 200 patients, median progression-free survival (PFS) for those receiving intermittent dosing of dabrafenib (Tafinlar) and trametinib (Mekinist) was 5.5 months, as compared to 9.0 months for patients receiving continuous treatment (HR 1.36, 80% CI 1.10-1.66, P=0.063), reported
BRAF/MEK combo raises risk of cardiovascular adverse events compared to BRAF monotherapy only
Three BRAF inhibitors -- dabrafenib, vemurafenib, and encorafenib -- are now approved by the FDA and the European Medicines Agency, as are three MEK inhibitors -- trametinib, cobimetinib, and binimetinib.
Do you know your tumor BRAF status? You probably should
Combined BRAF/MEK inhibition is an option that is recommended for BRAF-mutant patients, in light of the COMBI-AD study which showed higher relapse-free survival at 4 years with dabrafenib and trametinib compared with treatment with placebo.
GREAT NEWS: HEALTH CANADA APPROVES FIRST ADJUVANT TREATMENT FOR MELANOMA TO PREVENT RELAPSE FOLLOWING SURGERY!
Health Canada has just approved the use of a combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) to prevent recurrence of melanoma following surgery in patients with a stage II or stage III diagnosis, also referred to as ‘adjuvant’ treatment.